Cognition reports outcomes from trial of zervimesine for geographic atrophy

Cognition Therapeutics announced positive topline results from the Phase II MAGNIFY trial of zervimesine (CT1812) for treating geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD). The trial, which enrolled approximately 100 of the planned 246 subjects, was placebo-controlled and assessed changes in GA lesion size and growth rate. Results showed a 28.6% slower GA progression in patients treated with zervimesine, and after 18 months, the mean lesion size was 28.2% smaller than in the placebo group.

Nearly two-thirds of subjects completed one year of dosing, and one-third completed 18 months. The trial's voluntary conclusion allows Cognition to focus resources on its Alzheimer’s and dementia with Lewy bodies (DLB) programs. Zervimesine's potential as a once-daily oral treatment for dry AMD could offer a transformative alternative to current intravitreal injection-based treatments. 

12-05-2025